天花疫苗(Bavarian Nordic A/S)(Smallpox vaccine(Bavarian Nordic A/S)) - 在研适应症：猴痘，天花，牛痘病毒感染_专利_临床

概要

基本信息

药物类型

减毒活疫苗、预防性疫苗

别名

modified vaccinia Ankara - Bavarian Nordic (MVA-BN) virus、modified vaccinia Ankara virus、Modified Vaccinia Ankara-Bavarian Nordic

+ [11]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

权益机构

Bavarian Nordic A/S

Serum Institute of India Pvt Ltd.

上海强生制药有限公司

+ [1]

最高研发阶段批准上市

首次获批日期

欧盟 (2013-07-31),

猴痘天花牛痘病毒感染

最高研发阶段(中国)-

特殊审评紧急使用授权 (美国)

登录后查看时间轴

关联

35

项与天花疫苗(Bavarian Nordic A/S) 相关的临床试验

NCT05513313

/ Not yet recruitingN/A

Prospective Assessment of Myocarditis After Replication-Deficient Smallpox Immunization

This is a prospective observational phase IV study of a novel, replication-deficient smallpox vaccine that has been recently been approved by FDA. The purpose of this study is to determine if there are any abnormalities detected by electrocardiographic testing and/or blood tests within 35 days of receiving the second dose of smallpox vaccine either alone or co-administered with other vaccines that may/may not be suggestive of myopericarditis.

开始日期2029-03-01

申办/合作机构

Womack Army Medical Center

[+1]

NCT06829238

/ Recruiting临床4期IIT

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use (MET-IH)

This randomized clinical trial (RCT) evaluates whether metformin can reduce systemic inflammation and improve immune function in individuals with a history of injection drug use, with or without HIV. Participants will receive metformin or placebo and undergo immune system assessments, including vaccine response evaluations.

开始日期2025-04-07

申办/合作机构

The University of Alabama at Birmingham

[+1]

NCT06844487

/ Not yet recruiting临床3期IIT

Phase 3, Randomised Maternal and Infant (From 4 to 24 Months of Age) Safety and Immunogenicity Trial of MVA-BN® Vaccine in the Democratic Republic of the Congo

This Phase 3 double-blinded, randomized study aims to evaluate the safety and immunogenicity of the two-dose MVA-BN mpox vaccine regimen, administered subcutaneously, in infants and children aged 4 to 24 months in the Democratic Republic of the Congo (DRC), a population at high risk of mpox infection and complications. The study will compare the safety and immunogenicity of a full-dose regimen versus a half-dose regimen in this population. A hierarchical testing strategy will be applied as follows: first, non-inferiority of the full-dose regimen in infants/children (4-24 months old) will be evaluated against the full-dose regimen in adults from the POX-MVA-045 study. If non-inferiority is demonstrated, the immunogenicity of the half dose in infants/children (4-24 months old) will subsequently be tested for non-inferiority vs the full dose in adult. The trial will be conducted in Boende, Tshuapa Province, DRC.
The trial plans to enroll 344 male and female infants/children, who will be randomized to receive two doses of the MVA-BN vaccine administered 28 days apart. Participants in Child Group 1 (N=172) will receive the standard vaccine dose (0.5 mL), while those in Child Group 2 (N=172) will receive half the standard dose (0.25 mL), with both groups following the same dosing schedule.
This study builds on positive safety and immunogenicity data from prior trials that support the use of the standard dose regimen in younger children. However, considering the developmental differences in the immune systems of infants and young children/adolescents, it aims to evaluate whether a half-dose regimen can provide similar immunogenicity while potentially reducing reactogenicity. The findings will offer valuable insights into the optimal dosing strategy for this age group, balancing safety and immunogenicity to inform future vaccination recommendations.

开始日期2025-03-31

申办/合作机构

University of Antwerp

[+4]

100 项与天花疫苗(Bavarian Nordic A/S) 相关的临床结果

登录后查看更多信息

100 项与天花疫苗(Bavarian Nordic A/S) 相关的转化医学

登录后查看更多信息

100 项与天花疫苗(Bavarian Nordic A/S) 相关的专利（医药）

登录后查看更多信息

280

项与天花疫苗(Bavarian Nordic A/S) 相关的文献（医药）

2025-12-31·Virulence

Mpox: Global epidemic situation and countermeasures

Review

作者: Luo, Yinghua ; Jin, Chenghao ; Hou, Wenshuang ; Tang, Yanjun ; Wu, Nan ; Liu, Yanzhi ; Quan, Quan

Mpox, is a zoonotic disease caused by the monkeypox virus and is primarily endemic to Africa. As countries gradually stop smallpox vaccination, resistance to the smallpox virus is declining, increasing the risk of infection with mpox and other viruses. On 14 August 2024, the World Health Organization announced that the spread of mpox constituted a public health emergency of international concern. Mpox's transmission routes and symptoms are complex and pose new challenges to global health. Several vaccines (such as ACAM2000, JYNNEOS, LC16m8, and genetically engineered vaccines) and antiviral drugs (such as tecovirimat, brincidofovir, cidofovir, and varicella immunoglobulin intravenous injection) have been developed and marketed to prevent and control this disease. This review aims to introduce the epidemic situation, epidemiological characteristics, physiological and pathological characteristics, and preventive measures for mpox in detail, to provide a scientific basis for the prevention and control of mpox viruses worldwide.

2025-05-01·Lancet Regional Health-Europe

Correction to “Impact of vaccination with third generation modified vaccinia Ankara and sexual behaviour on mpox incidence in men who have sex with men: analysis among participants of the ANRS-174 DOXYVAC trial” [The Lancet Regional Health—Europe 45, October 2024, 101020]

作者: Rubenstein, Emma ; Molina, Jean-Michel ; Viard, Jean-Paul ; Gibowski, Severine ; Ghosn, Jade ; Costagliola, Dominique ; Pialoux, Gilles ; Ollivier, Manon ; Pavie, Juliette ; Algarte-Genin, Michèle ; Duvivier, Claudine ; Ouattara, Moussa ; Katlama, Christine ; Assoumou, Lambert ; Surgers, Laure

[This corrects the article DOI: 10.1016/j.lanepe.2024.101020.].

2025-04-15·JOURNAL OF INFECTIOUS DISEASES

Monkeypox Virus Infection Stimulates a More Robust and Durable Neutralizing Antibody Response Compared to Modified Vaccinia Virus Ankara Vaccination

Article

作者: Selverian, Christopher N ; Meyerowitz, Eric ; DeMouth, Megan E ; Herbert, Andrew S ; Battini, Leandro ; Miller, Emily Happy ; Meola, Annalisa ; Lasso, Gorka ; Jaleta, Yakin M ; Berrigan, Jacob ; Chandran, Kartik ; Batchelor, Thomas G ; Guardado-Calvo, Pablo ; Monticelli, Stephanie R

Abstract:

Monkeypox virus (MPXV) has recently caused a global disease outbreak in humans. Differences in the neutralizing antibody response to vaccination versus MPXV infection remain poorly understood. Here, we examined the neutralization of MPXV and vaccinia virus by sera from a cohort of convalescent and vaccinated individuals at 1 and 8 months postexposure. Convalescent individuals displayed higher neutralizing antibody titers against MPXV than vaccinated and MPXV-naive persons at 1 month postexposure. Neutralizing antibody titers had waned significantly in both groups at 8 months. This study suggests that additional vaccine strategies are needed to elicit a durable humoral response and prevent breakthrough infections.

360

项与天花疫苗(Bavarian Nordic A/S) 相关的新闻（医药）

2025-05-09

·GlobeNewswire-Health Care

Bavarian Nordic Announces Interim Results for the First Three Months of 2025

COPENHAGEN, Denmark, May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. Revenue for the first three months increased by 62% to DKK 1,347 million, reflecting a strong performance in both Travel Health and Public Preparedness. Travel Health revenue increased by 52% to DKK 680 million compared to the first quarter of 2024, primarily driven by increased demand for rabies and tick-borne encephalitis (TBE) vaccines.Public Preparedness revenue increased by 83% to DKK 629 million compared to the first quarter of 2024. This exceeded initial expectations due to successful efforts to advance the deliveries of a few, but larger, existing orders into the first quarter.Other revenue was DKK 37 million. The operating profit (EBITDA) was DKK 420 million, corresponding to an EBITDA margin of 31%.Financial guidance for the full year is maintained at a revenue of DKK 5,700-6,700 million and an EBITDA margin of 26-30%. DKK million3m 20253m 20242025 GuidanceRevenue1,3478315,700 – 6,700EBITDA margin31%3%26-30% Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “A very strong first quarter for our Travel Health business, demonstrating a 52% growth year-over-year and puts us ahead of our strategic goal of an average annual growth rate of 10-12% for this part of the business until 2027. We also recorded our first US sales of the chikungunya vaccine after its approval in February and ahead of the April recommendation from ACIP. Our phased launch plan for the vaccine is progressing as planned with the first European markets coming online over the next couple of months while we also continue our efforts to expand the regulatory approvals to other territories. Chikungunya represents an increasing public health threat across the globe, and we are proud to have entered our first partnership to improve access to the vaccine for low- and middle-income countries. In Public Preparedness, we also delivered above expectations. While this was largely due to a number of deliveries occurring ahead of plans, it goes to show the strength and scale of our manufacturing setup to meet the increased demand for our mpox/smallpox vaccine.” Highlights from the first quarter Travel Health Vimkunya was approved in the US and EU in February as the first virus-like particle (VLP)-based chikungunya vaccine and the first chikungunya vaccine for persons aged 12 years and older. Additionally, regulatory submissions were filed in the UK and Canada.Vimkunya was launched commercially in the US in March and will be launched in the first European markets later during the first half of 2025.Concurrently with the US approval of Vimkunya, Bavarian Nordic was granted a Priority Review Voucher, which the Company intends to monetize when appropriate.A strategic partnership was entered with Biological E. Limited in February, initially comprising a contract manufacturing agreement with the aim to provide capacity for the future supply of chikungunya vaccines to endemic low- and middle-income countries. Public Preparedness The freeze-dried version of JYNNEOS was approved by the U.S. Food and Drug Administration (FDA) in March for prevention of smallpox and mpox disease in adults 18 years of age and older. The approval supports the ongoing contract with the US government for stockpiling of the vaccine. Other business In January, Bavarian Nordic launched and completed a share buy-back program of DKK 150 million, with the purpose of adjusting the capital structure. Events after the reporting date In April, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Vimkunya™ for the prevention of disease caused by chikungunya virus for US persons aged 12 and older traveling to regions with an outbreak or elevated risk of chikungunya, as well as for laboratory workers with potential for exposure to chikungunya virus.In May, the UK Medicines and Healthcare products Regulatory Agency granted marketing authorization in the United Kingdom for Vimkunya® for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older.In May, the US government exercised additional options valued at USD 143.6 million under the existing contract to supply a freeze-dried formulation of JYNNEOS® smallpox vaccine, with planned delivery in 2026. Conference call and webcastThe management of Bavarian Nordic will host an investor/analyst call today at 2 pm CEST (8 am EDT) to present the interim results followed by a Q&A session. A listen-only version of the call and presentation slides can be accessed via https://edge.media-server.com/mmc/p/798tzbob/. To join the Q&A session, please register in advance via https://register-conf.media-server.com/register/BI2a5d49d1c9d64ee99d6d03297d3d4323. Contact investors:Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600 Contact media:Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03 Company Announcement no. 16 / 2025 About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Attachment Interim Report Q1 2025

上市批准疫苗财报加速审批引进/卖出

2025-05-09

·Pharmaceutical Technology

Bavarian Nordic shares rise 7% following strong Q1 for vaccine sales

Bavarian Nordic has recently secured had key vaccine approvals for chikungunya virus and mpox/smallpox. Image credit: Shutterstock / Anne Czichos. Bavarian Nordic is successfully navigating a sentiment-changing vaccine landscape, posting Q1 revenues significantly up from the same period in 2024. The Danish vaccine specialist reported quarterly revenue of DKr1.3bn ($200m), a 62% year-over-year increase. Bavarian Nordic maintained its full year guidance of DKr5.7-DKr6.7bn. Shares in the company opened 7% higher at a price of DKr167.15 at market open, following the announcement made early on 9 May. Bavarian Nordic faced a challenging close to 2024, with Q3 revenue falling 26% compared to the same interval in 2023. Across the first nine months of the fiscal year 2024, the company experienced a 46% deficit. After some key approvals and contract signings, Bavarian Nordic has turned a corner, and its 2025 start makes for some strong financial reading. Revenue for Bavarian Nordic’s travel health business, which includes chikungunya vaccine Vimkunya and rabies shot Rabipur amongst others, increased 52% to Dkr680m. The company stated it was Rabipur and tick-borne encephalitis (TBE) vaccine Encepur that drove the higher sales compared to 2024. Vimkunya was approved in the US and UK in February, becoming the second commercially available jab alongside Valneva’s Ixchiq. Bavarian Nordic could be set for a market advantage as the vaccine is approved for people aged 12 years and older while Ixchiq is only licensed for adults. As of 8 May, Ixchiq is also under review by the European Medicines Agency (EMA) amid reports of serious side effects. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Vimkunya will likely contribute to revenue from Q2 onwards, having been launched in the US in March and set for European markets in H1 2025. Bavarian Nordic received a priority review voucher, which it expects to monetise, as part of Vimkunya’s US approval . Voucher sales have historically averaged at around $100m, facilitating a quick cash injection to biotechs selling them. For its public preparedness business, headed by smallpox/mpox vaccine Jynneos, revenue was up an immense 83% to reach Dkr629m. Bavarian Nordic stated this “exceeded initial expectations” due to orders advanced early into Q1. The company secured a regulatory win when the US Food and Drug Administration (FDA) approved a freeze-dried formulation of Jynneos, supporting the ongoing contract with the US government for stockpiling. This includes recently exercised additional options valued at $144m within the Jynneos stockpiling contract. Vaccines are under the spotlight due to a polarised landscape in the US. Health Secretary Robert F Kennedy, Jr. has voiced anti-vaccine rhetoric and doubled down on scientifically false claims. In a move last week that upped confidence from infectious disease-specialist biotechs, however, the US Department of Health and Human Services (HHS) launched a $500m initiative to accelerate the development of universal vaccines targeting viruses with pandemic potential.

疫苗上市批准

2025-05-06

·GlobeNewswire-Health Care

Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox Vaccines

Exercised options total USD 143.6 millionSecures manufacturing and supply of freeze-dried JYNNEOS® to the U.S. in 2026 COPENHAGEN, Denmark, May 6, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), has exercised additional options valued at USD 143.6 million under the existing contract to supply a freeze-dried formulation of JYNNEOS® smallpox vaccine. The options support the manufacturing and supply of freeze-dried JYNNEOS by conversion of bulk vaccine, previously manufactured under other contract options, as well as supplemental payments for all doses procured under the freeze-dried contract, triggered by the demonstration of an extended shelf-life. The supplemental payments will be invoiced pro rata with deliveries of the freeze-dried vaccines. Deliveries under the new contract options are planned for 2026. Bavarian Nordic’s financial guidance for 2025 remains unchanged at total revenues of DKK 5,700-6,700 million and an EBITDA margin of 26-30%. From the Public Preparedness business, revenue of DKK 3,000-4,000 million is still expected, of which DKK 2,650 million has been secured, which is an increase of DKK 150 million following exercise of the options. Paul Chaplin, President & CEO of Bavarian Nordic, said: “Following the recent FDA approval of the freeze-dried formulation of our smallpox/mpox vaccine, we applaud the U.S. government’s steadfast commitment to improving national health security through the exercise of these options. The freeze-dried vaccine, with its improved shelf life, provides a significant contribution to securing the long-term availability of countermeasures to protect U.S citizens against life-threatening diseases.” About our contracts with the U.S. governmentSince 2003, Bavarian Nordic has worked with the U.S. government on the development, manufacturing and supply of a non-replicating smallpox vaccine to ensure all populations can be protected from smallpox and mpox, including people with weakened immune systems who are at high risk of adverse reactions to traditional smallpox vaccines, which are based on replicating vaccinia virus strains. Approved by the FDA in 2019, JYNNEOS was the first smallpox vaccine successfully developed under Project BioShield, a program created by the U.S. Congress in 2004 to accelerate the research, development, procurement, and availability of medical countermeasures against biological, chemical, radiological, and nuclear (CBRN) threats through public-private partnerships. Bavarian Nordic has supplied a liquid-frozen formulation of JYNNEOS to the U.S. government for stockpiling since 2010 and in response to the mpox outbreak in 2022-2023. BARDA has supported the development of a freeze-dried formulation of the vaccine to replenish the stockpile and in 2017 awarded the Company a ten-year contract, which includes options valued at USD 299 million for the fill and finish of freeze-dried vaccines, of which USD 284 million has been exercised to-date. The freeze-dried formulation of JYNNEOS, approved by the FDA in March 2025, provides certain advantages over the liquid-frozen formulation in terms of transportation, storage conditions and shelf life, all of which are important factors for long-term stockpiling. This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201700019C. About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors:Europe: Rolf Sass Sørensen, Vice President Investor Relations, rss@bavarian-nordic.com, Tel: +45 61 77 47 43US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600 Contact media:Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com, Tel: +45 53 88 06 03 Company Announcement no. 15 / 2025 Attachment 2025-15-en

疫苗上市批准

100 项与天花疫苗(Bavarian Nordic A/S) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	天花疫苗(Bavarian Nordic A/S)	J07BX	DB15483

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
猴痘	欧盟	Bavarian Nordic A/S	2013-07-31
猴痘	冰岛	Bavarian Nordic A/S	2013-07-31
猴痘	列支敦士登	Bavarian Nordic A/S	2013-07-31
猴痘	挪威	Bavarian Nordic A/S	2013-07-31
天花	欧盟	Bavarian Nordic A/S	2013-07-31
天花	冰岛	Bavarian Nordic A/S	2013-07-31
天花	列支敦士登	Bavarian Nordic A/S	2013-07-31
天花	挪威	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	欧盟	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	冰岛	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	列支敦士登	Bavarian Nordic A/S	2013-07-31
牛痘病毒感染	挪威	Bavarian Nordic A/S	2013-07-31

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
怀孕	临床3期	美国	Bavarian Nordic A/S	2025-03-31
特应性皮炎	临床2期	美国	Bavarian Nordic A/S	2006-07-01
特应性皮炎	临床2期	墨西哥	Bavarian Nordic A/S	2006-07-01
HIV感染	临床2期	美国	Bavarian Nordic A/S	2006-06-01
HIV感染	临床2期	波多黎各	Bavarian Nordic A/S	2006-06-01
季节性过敏性鼻炎	临床1期	德国	Bavarian Nordic A/S	2004-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05512949 (NEWS) 人工标引	临床2期	猴痘	229	MVA-BN (aged between 12 and 17 years)	獵壓廠膚衊網淵蓋顧繭(觸簾範觸選壓範積繭築) = After two doses, antibody levels were found to be equivalent at day 43 to those in adults aged 18 to 50 years. 積鑰鑰築鑰鑰艱淵襯製 (淵襯餘艱製願鏇範鑰齋 ) 更多	积极	2024-10-17
Literature 人工标引	N/A	猴痘	45	MVA-BN 2 doses	醖蓋襯遞積糧壓膚簾廠(醖糧膚憲築膚憲觸夢築) = 2 doses: mpox M1R, B6R, A35R, A29L, and H3L antigens peaked at 112, 384, 85, 29, and 76 at week 3 after vaccination but then declined to 38, 82, 32, 25, and 31 at 12 months; 1 dose: the median binding antibody ELISA titers to mpox M1R, B6R, A35R, A29L, and H3L antigens peaked at 45, 90, 32, 31, and 28 at week 3 but then declined to 33, 43, 30, 25, and 28 at 12 months 醖積鑰壓糧網夢壓齋鑰 (觸鬱夢餘積網齋餘憲艱 )	不佳	2024-10-03
				MVA-BN 1 doses
NCT05740982 (NEWS) 人工标引	临床2期	埃博拉病毒性疾病	526	IMVANEX (adolescents 12-17 years of age)	鹹選膚鹹鬱艱糧壓廠簾(衊壓顧繭遞醖膚積壓淵) = a similar safety profile between both age groups 廠獵選鬱網製鬱構構鏇 (獵襯鑰艱遞範蓋襯簾顧 ) 更多	积极	2024-09-19
				IMVANEX (adults aged 18 years and older)
NCT05512949 (CTgov)	临床2期	猴痘	229	MVA-BN (2 x 10^7 ID MVA-BN)	顧鬱簾鏇夢蓋範壓蓋觸(鹹鏇淵齋鑰鏇鹽選醖構) = 齋餘鑰願繭糧齋範窪淵鏇顧窪鹽壓鑰蓋獵夢餘 (衊醖襯糧鹹構鑰夢製醖, 衊膚簾襯繭願襯網構鬱 ~ 繭衊糧獵鹽網鬱願鑰壓) 更多	-	2024-01-09
				MVA-BN (1 x 10^7 ID MVA-BN)	顧鬱簾鏇夢蓋範壓蓋觸(鹹鏇淵齋鑰鏇鹽選醖構) = 範窪積糧齋鹹膚齋艱範鏇顧窪鹽壓鑰蓋獵夢餘 (衊醖襯糧鹹構鑰夢製醖, 選蓋齋選蓋憲簾範艱淵 ~ 鬱鹹選網鑰顧簾鹹醖鹽) 更多
NCT03699124 (Pubmed) 人工标引	临床3期	-	1,129	MVA-BN	願獵顧願鏇餘艱鏇醖艱(餘製鹹鹹鏇襯鏇膚膚構) = 蓋範繭鏇鬱鹽夢製觸鏇壓觸鹹獵選願製糧夢艱 (繭鬱壓觸憲醖遞鏇憲範 ) 更多	积极	2022-11-29
NCT03699124 (CTgov)	临床3期	天花	1,129	FD MVA-BN (GP 1: Two Doses of FD MVA-BN--Lot 1)	齋窪觸齋選簾餘淵夢鏇(築襯鏇顧獵範範膚範鹽) = 簾膚築鏇糧範窪膚遞觸範蓋襯齋獵築範鑰獵築 (壓壓鏇獵淵鑰齋餘願醖, 築鹽夢憲鏇構襯遞蓋廠 ~ 製鬱繭淵繭顧築糧範鹹) 更多	-	2021-05-27
				FD MVA-BN (GP 2: Two Doses of FD MVA-BN--Lot 2)	齋窪觸齋選簾餘淵夢鏇(築襯鏇顧獵範範膚範鹽) = 鹹齋獵範鑰選衊窪願簾範蓋襯齋獵築範鑰獵築 (壓壓鏇獵淵鑰齋餘願醖, 築鹽餘窪積蓋艱築簾鏇 ~ 積積簾窪醖襯糧願鏇艱) 更多
NCT01668537 (CTgov)	临床2期	天花	651	LF (LF Formulation)	構願鏇廠齋築廠簾鑰糧(繭網艱鑰簾鹽窪膚製網) = 構築襯積膚選餘鹽顧簾鑰齋鏇憲積鹽襯繭襯廠 (壓憲糧糧夢顧範壓構鹽, 壓艱艱壓願網艱壓窪襯 ~ 鹹鑰製顧鹽餘網願廠選) 更多	-	2020-10-12
				MVA-BN (FD Formulation)	構願鏇廠齋築廠簾鑰糧(繭網艱鑰簾鹽窪膚製網) = 夢壓願鹽蓋鏇積糧觸鏇鑰齋鏇憲積鹽襯繭襯廠 (壓憲糧糧夢顧範壓構鹽, 衊廠窪築遞憲鏇糧窪糧 ~ 獵遞繭餘網壓廠繭簾蓋) 更多
NCT03472014 (CTgov)	临床4期	-	22	MVA-BN	鑰獵觸艱憲選鏇範壓壓 = 憲顧構顧顧簾鹽鬱構襯築淵簾繭繭鬱糧鑰壓簾 (鏇淵醖鬱簾襯顧壓廠餘, 積夢構鹽築積壓憲網膚 ~ 觸製繭蓋鹽蓋憲積簾淵) 更多	-	2020-08-19
NCT01913353 (Pubmed \| Br Dent J \| N Engl J Med) 人工标引	临床3期	天花	433	modified vaccinia Ankara+ACAM2000	衊憲鹽範鹹選夢鹽鹹簾(鹽艱夢網選夢蓋築鬱糧): RO = 97.9 (95% CI, 96.6 ~ 98.3) 更多	优效	2019-11-14
				ACAM2000
NCT00686582 (CTgov)	临床2期	天花	304	IMVAMUNE (Initially Vaccinia Naive, 2 Dose Primed, 1 Booster Dose)	鹽觸鏇憲糧顧製窪觸憲 = 醖願鏇願範鑰醖繭鬱選餘蓋壓齋鹽壓觸製醖衊 (廠廠廠願衊夢齋齋蓋襯, 願鬱糧選鹹遞繭鹽鹽觸 ~ 憲憲鑰鬱醖觸製齋構壓) 更多	-	2019-02-18
				IMVAMUNE (Initially Vaccinia Naive, 1 Dose Primed, 1 Booster Dose)	鹽觸鏇憲糧顧製窪觸憲 = 網構積鑰獵襯廠壓鏇襯餘蓋壓齋鹽壓觸製醖衊 (廠廠廠願衊夢齋齋蓋襯, 衊遞顧廠鑰遞範艱餘艱 ~ 鬱簾艱製製餘衊艱積選) 更多